A critical assessment of vector control for dengue prevention.

Achee NL, Gould F, Perkins TA, Reiner RC, Morrison AC, Ritchie SA, Gubler DJ, Teyssou R, Scott TW. · 2015

Read A critical assessment of vector control for dengue prevention. by Achee NL, Gould F, Perkins TA, Reiner RC, Morrison AC, Ritchie SA, Gubler DJ, Teyssou R, Scott TW. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4423954.txt.

Introduction

Nicole Achee and nine co-authors, including Scott Halstead, gave a critical review in PLoS Neglected Tropical Diseases in 2015 of mosquito control for dengue. Dengue has no single fix, and even when a vaccine is sold, the authors argue, control of the mosquitoes that carry the virus will still be needed alongside it.

Working for the Partnership for Dengue Control, the group assessed tools in use and tools still being built, from spraying and larval control to newer genetic and biological methods. They set out a research plan to learn, with firm proof, which tools work best and how to combine them. The aim is practical guidance for programs that now choose methods with limited hard evidence.

Catalog record

CREATORAchee NL, Gould F, Perkins TA, Reiner RC, Morrison AC, Ritchie SA, Gubler DJ, Teyssou R, Scott TW.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE73 KB
LICENSECC0 1.0 Universal
RIGHTSCC0
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4423954

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Critical Assessment of Vector Control for Dengue Prevention By Nicole L. Achee, Fred Gould, T. Alex Perkins, Robert C. Reiner, Amy C. Morrison, Scott A. Ritchie, Duane J. Gubler, Remy Teyssou, Thomas W. Scott, Scott B Halstead Published in: PLoS Neglected Tropical Diseases DOI: 10.1371/journal.pntd.0003655 ABSTRACT Recently, the Vaccines to Vaccinate (v2V) initiative was reconfigured into the Partnership for Dengue Control (PDC), a multi-sponsored and independent initiative. This redirection is consistent with the growing consensus among the dengue-prevention community that no single intervention will be sufficient to control dengue disease. The PDC's expectation is that when an effective dengue virus (DENV) vaccine is commercially available, the public health community will continue to rely on vector control because the two strategies complement and enhance one another. Although the concept of integrated intervention for dengue prevention is gaining increasingly broader acceptance, to date, no consensus has been reached regarding the details of how and what combination of approaches can be most effectively implemented to manage disease. To fill that gap, the PDC proposed a three step process: (1) a critical assessment of current vector control tools and those under development, (2) outlining a research agenda for determining, in a definitive way, what existing tools work best, and (3) determining how to combine the best vector control options, which have systematically been defined in this process, with DENV vaccines. To address the first step, the PDC convened a meeting of international experts during November 2013 in Washington, DC, to critically assess existing vector control interventions and tools under development. This report summarizes those deliberations. INTRODUCTION Dengue virus (DENV) causes more human morbidity and mortality than any other arboviral disease. Recent estimates are that approximately 390 million people are infected each year and 96 million manifest with clinically apparent disease [1]. The World Health Organization (WHO) called for an increased focus on dengue prevention in its 2013 report on neglected tropical diseases. Dengue’s explosive epidemic potential and the worldwide increase in dengue cases was noted. Specifically, dengue has experienced a 30-fold increase in incidence over the past 50 years that shows no sign of slowing down. The report calls for evaluation and integration of current intervention strategies to achieve a 50% reduction in dengue mortality and 25% reduction in dengue morbidity by 2020 [2]. DENV is transmitted from one person to another by Aedes mosquitoes, principally Aedes aegypti [3]. Human infections can result in a spectrum of diseases ranging from mild, self-limiting febrile illness to classic dengue fever to shock syndrome and death [4], but it has been recognized that the majority of infections are mild or show no clinical manifestations. Presently, there are no commercially available antivirals or dengue vaccines, though progress on their development is encouraging [5–11]. Dengue prevention, therefore, is currently limited to mosquito control. A few well-documented successes indicate that rigorously applied vector control can reduce DENV transmission and disease. During the 1950s and 1960s a regional program across much of the Caribbean and Central and South America dramatically reduced Ae. aegypti populations, resulting in striking reductions in human yellow fever and DENV infections and purported elimination of Ae. aegypti from most of the region by the early 1970s [12,13]. Vector control programs for dengue control in Singapore during the 1970s and 1980s [14] and in Cuba during the 1980s and 1990s [15–17] are similarly recognized as public health successes, but they, too, were unfortunately not sustainable. The inability of these countries to sustain their gains is considered, at least in part, to be the consequence of diminished herd immunity [18]. This is worth emphasizing, particularly in the context of envisaged vaccination programmes, which may help overcome the problem of vector control sustainability by elevating herd immunity [19]. Less dramatic results, for example during 2000–2010 in Peru, were seen by the successful use of emergency vector control to reduce the force of DENV infection [20], i.e., per capita risk of human infection [19]. There is, however, considerable frustration because vector control has failed to prevent epidemics and DENV’s expanding geographic distribution [21]. Although the concept of vector control is reasonable, control must be early in an outbreak or strategically applied during inter-epidemic periods to prevent escalation in transmission and successful broad scale application has been difficult to achieve (Box 1). Box 1. Key Learning Points from Vector Control for Dengue PreventionSuccess in reducing the public health burden of dengue will require a multi-pronged approach that includes developing the underlying theory of effective dengue control, continuing to review and assess existing interventions and strategies, and gathering new empirical data that tests fundamental concepts and strategies. This is best achieved through:Controlled experimental studies are urgently needed to assess the health impact of dengue vector control based on epidemiological and entomological metrics. Interventions under development are required to address this issue. The gap is greatest for existing tools and strategies, which were developed in an era when epidemiologic assessments were not carried out.Although greater emphasis should be placed on proactive strategies that aim to prevent, diminish, or eliminate transmission, dengue outbreaks occur and response requires attention to development of tools and strategies that can be rapidly deployed and have swift impact.Dengue is a growing problem in modern mega-urban centers that span across countries and regions. Scaling up from successful small-scale experimental trials to broad-scale public health application is among the biggest challenges for improving mosquito control for dengue prevention.There is a growing consensus that eliminating dengue as a public health burden can only be achieved by integrating vector control with vaccines. Prioritizing the vector interventions based on their potential to prevent disease will facilitate determining how to combine the best options with DENV vaccines. Mission of the Partnership for Dengue Control The initiative Vaccines to Vaccination (v2V) was established in 2009 to facilitate delivery of DENV vaccines following regulatory approval. After publication of results from a phase 2b clinical dengue vaccine trial in Thailand indicating varying levels of vaccine efficacy [9], the program was reconfigured into the Partnership for Dengue Control (PDC), a multi-sponsored and independent initiative. Redirection of the program was consistent with the growing consensus among the dengue prevention community that no single intervention will be sufficient to control dengue disease. This is due to heterogeneities in mosquito vector, viral pathogen, and human host factors that drive the complexity of transmission. It was decided, therefore, that, for the greatest likelihood of sustained dengue prevention, the PDC mission should be to promote development and implementation of multiple innovative, integrated, and synergistic interventions. The PDC’s expectation is that when an effective DENV vaccine is commercially available, the public health community will continue to rely on vector control because the two strategies complement and enhance one another [19]. A dengue vaccine can be used to artificially elevate herd immunity and vector control to lower the force of infection. Theory and results from field studies with other vector-borne pathogens support the power of simultaneously targeting the vector and pathogen. The global malaria burden has been reduced using anti-Plasmodium drugs in conjunction with insecticide-treated bed nets [22–25]. Lymphatic filariasis (LF) is more rapidly and efficiently managed when anti-parasite drugs are combined with vector control than when drugs alone are used [26–32]. As has been the

Read the complete text